

Jeffrey A Cohen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2034013/publications.pdf>

Version: 2024-02-01

156
papers

27,495
citations

41627

51
h-index

10955

142
g-index

160
all docs

160
docs citations

160
times ranked

21004
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. <i>Annals of Neurology</i> , 2011, 69, 292-302.	2.8	8,001
2	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , The, 2018, 17, 162-173.	4.9	4,605
3	Defining the clinical course of multiple sclerosis. <i>Neurology</i> , 2014, 83, 278-286.	1.5	2,344
4	Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2010, 362, 402-415.	13.9	1,983
5	Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. <i>Lancet</i> , The, 2012, 380, 1819-1828.	6.3	1,041
6	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. <i>Lancet</i> , The, 2012, 380, 1829-1839.	6.3	1,040
7	Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. <i>Multiple Sclerosis Journal</i> , 2008, 14, 383-390.	1.4	535
8	A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. <i>Nature</i> , 1989, 339, 230-231.	13.7	432
9	Ofatumumab versus Teriflunomide in Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2020, 383, 546-557.	13.9	358
10	Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis. <i>Annals of Neurology</i> , 2011, 69, 759-777.	2.8	344
11	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview. <i>Multiple Sclerosis Journal</i> , 2015, 21, 263-281.	1.4	273
12	Validity of the timed 25-foot walk as an ambulatory performance outcome measure for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 704-710.	1.4	270
13	Progressive multiple sclerosis: prospects for disease therapy, repair, and restoration of function. <i>Lancet</i> , The, 2017, 389, 1357-1366.	6.3	235
14	Alemtuzumab CARE-MS II 5-year follow-up. <i>Neurology</i> , 2017, 89, 1117-1126.	1.5	232
15	Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. <i>Lancet Neurology</i> , The, 2012, 11, 467-476.	4.9	211
16	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology</i> , The, 2011, 10, 520-529.	4.9	204
17	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (SUNBEAM): a multicentre, randomised, minimum 12-month, phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 1009-1020.	4.9	191
18	Alemtuzumab CARE-MS I 5-year follow-up. <i>Neurology</i> , 2017, 89, 1107-1116.	1.5	188

#	ARTICLE	IF	CITATIONS
19	Safety and efficacy of ozanimod versus interferon beta-1a in relapsing multiple sclerosis (RADIANCE): a multicentre, randomised, 24-month, phase 3 trial. <i>Lancet Neurology</i> , The, 2019, 18, 1021-1033.	4.9	184
20	Vision and vision-related outcome measures in multiple sclerosis. <i>Brain</i> , 2015, 138, 11-27.	3.7	168
21	Use of the Multiple Sclerosis Functional Composite as an Outcome Measure in a Phase 3 Clinical Trial. <i>Archives of Neurology</i> , 2001, 58, 961.	4.9	151
22	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial. <i>Lancet Neurology</i> , The, 2016, 15, 373-381.	4.9	150
23	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017, 140, 2776-2796.	3.7	139
24	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 468-475.	0.9	137
25	Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. <i>Neurology</i> , 2014, 82, 674-680.	1.5	135
26	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015, 21, 282-293.	1.4	131
27	Symbol Digit Modalities Test: A valid clinical trial endpoint for measuring cognition in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1781-1790.	1.4	129
28	Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. <i>Neurology</i> , 2015, 84, 784-793.	1.5	119
29	Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. <i>CNS Drugs</i> , 2015, 29, 565-575.	2.7	117
30	Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions. <i>Lancet</i> , The, 2021, 398, 1184-1194.	6.3	113
31	Mesenchymal stem cell transplantation in multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2013, 333, 43-49.	0.3	110
32	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	4.9	110
33	Combination therapy in multiple sclerosis. <i>Lancet Neurology</i> , The, 2010, 9, 299-308.	4.9	106
34	Fingolimod in relapsing multiple sclerosis: An integrated analysis of safety findings. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 494-504.	0.9	105
35	Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. <i>Neurotherapeutics</i> , 2017, 14, 859-873.	2.1	105
36	The EDSS-Plus, an improved endpoint for disability progression in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017, 23, 94-105.	1.4	95

#	ARTICLE	IF	CITATIONS
37	Advances in oral immunomodulating therapies in relapsing multiple sclerosis. <i>Lancet Neurology</i> , The, 2020, 19, 336-347.	4.9	90
38	Pilot trial of intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 501-511.	1.4	86
39	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. <i>Journal of Neurology</i> , 2013, 260, 2023-2032.	1.8	82
40	The Potential for Vigabatrin-Induced Intramyelinic Edema in Humans. <i>Epilepsia</i> , 2000, 41, 148-157.	2.6	75
41	Human Mesenchymal Stem Cells Impact Th17 and Th1 Responses Through a Prostaglandin E2 and Myeloid-Dependent Mechanism. <i>Stem Cells Translational Medicine</i> , 2016, 5, 1506-1514.	1.6	73
42	The 2013 clinical course descriptors for multiple sclerosis. <i>Neurology</i> , 2020, 94, 1088-1092.	1.5	73
43	Reciprocal Th1 and Th17 regulation by mesenchymal stem cells: Implication for multiple sclerosis. <i>Annals of Neurology</i> , 2010, 68, 540-545.	2.8	69
44	Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 845-854.	2.0	69
45	First-dose effects of fingolimod: Pooled safety data from three phase 3 studies. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 629-638.	0.9	68
46	Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 1433.	4.5	67
47	Phase III dose-comparison study of glatiramer acetate for multiple sclerosis. <i>Annals of Neurology</i> , 2011, 69, 75-82.	2.8	65
48	Multiple Sclerosis: New Insights in Pathogenesis and Novel Therapeutics. <i>Annual Review of Medicine</i> , 2012, 63, 389-404.	5.0	64
49	Recommendations for observational studies of comorbidity in multiple sclerosis. <i>Neurology</i> , 2016, 86, 1446-1453.	1.5	64
50	Multiple sclerosis management during the COVID-19 pandemic. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1163-1171.	1.4	63
51	Evaluation of multiple sclerosis disability outcome measures using pooled clinical trial data. <i>Neurology</i> , 2019, 93, e1921-e1931.	1.5	58
52	Infection risk with alemtuzumab decreases over time: pooled analysis of 6-year data from the CAMMS223, CARE-MS I, and CARE-MS II studies and the CAMMS03409 extension study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1605-1617.	1.4	57
53	Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients. <i>Neurology</i> , 2016, 87, 1985-1992.	1.5	55
54	Leveraging real-world data to investigate multiple sclerosis disease behavior, prognosis, and treatment. <i>Multiple Sclerosis Journal</i> , 2020, 26, 23-37.	1.4	55

#	ARTICLE	IF	CITATIONS
55	Extended treatment with fingolimod for relapsing multiple sclerosis: the 14-year LONGTERMS study results. <i>Therapeutic Advances in Neurological Disorders</i> , 2019, 12, 175628641987832.	1.5	54
56	COVID-19 in people with multiple sclerosis: A global data sharing initiative. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1157-1162.	1.4	50
57	Effect of Template Reporting of Brain MRIs for Multiple Sclerosis on Report Thoroughness and Neurologist-Rated Quality: Results of a Prospective Quality Improvement Project. <i>Journal of the American College of Radiology</i> , 2017, 14, 371-379.e1.	0.9	49
58	The challenge of comorbidity in clinical trials for multiple sclerosis. <i>Neurology</i> , 2016, 86, 1437-1445.	1.5	48
59	Early tolerability and safety of fingolimod in clinical practice. <i>Journal of the Neurological Sciences</i> , 2012, 323, 167-172.	0.3	44
60	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 12-month follow-up. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 44-52.	0.9	43
61	Fingolimod Therapy for Multiple Sclerosis. <i>Seminars in Neurology</i> , 2013, 33, 037-044.	0.5	42
62	The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing/Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1704-1713.	1.4	41
63	The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1469-1484.	1.4	41
64	Multiple sclerosis symptom management. <i>Expert Review of Neurotherapeutics</i> , 2007, 7, 1213-1222.	1.4	39
65	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review. <i>Multiple Sclerosis Journal</i> , 2015, 21, 332-341.	1.4	39
66	Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1255-1262.	1.4	37
67	Applying the 2017 McDonald diagnostic criteria for multiple sclerosis – Authors' reply. <i>Lancet Neurology</i> , The, 2018, 17, 499-500.	4.9	35
68	Intrinsic and Extrinsic Mechanisms of Thalamic Pathology in Multiple Sclerosis. <i>Annals of Neurology</i> , 2020, 88, 81-92.	2.8	33
69	Clinical outcome measures for progressive MS trials. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1627-1635.	1.4	32
70	Experience with fingolimod in clinical practice. <i>International Journal of Neuroscience</i> , 2015, 125, 678-685.	0.8	31
71	Determining the effectiveness of early intensive versus escalation approaches for the treatment of relapsing-remitting multiple sclerosis: The DELIVER-MS study protocol. <i>Contemporary Clinical Trials</i> , 2020, 95, 106009.	0.8	31
72	Superior MRI outcomes with alemtuzumab compared with subcutaneous interferon β -1a in MS. <i>Neurology</i> , 2016, 87, 1464-1472.	1.5	28

#	ARTICLE	IF	CITATIONS
73	Comparative efficacy and discontinuation of dimethyl fumarate and fingolimod in clinical practice at 24-month follow-up. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2017, 3, 205521731771548.	0.5	28
74	Emerging Therapies for Relapsing Multiple Sclerosis. <i>Archives of Neurology</i> , 2009, 66, 821-8.	4.9	27
75	Safety of monoclonal antibodies for the treatment of multiple sclerosis. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 89-100.	1.0	27
76	Long-term prognostic value of longitudinal measurements of blood neurofilament levels. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, .	3.1	27
77	Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis. <i>CNS Drugs</i> , 2021, 35, 985-997.	2.7	26
78	Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1423-1437.	0.9	25
79	Discontinuation and comparative effectiveness of dimethyl fumarate and fingolimod in 2 centers. <i>Neurology: Clinical Practice</i> , 2018, 8, 292-301.	0.8	25
80	Efficacy and safety of ofatumumab in recently diagnosed, treatment-naïve patients with multiple sclerosis: Results from ASCLEPIOS I and II. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1562-1575.	1.4	25
81	Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1909-1917.	1.4	23
82	Movement disorders in early MS and related diseases. <i>Neurology: Clinical Practice</i> , 2019, 9, 24-31.	0.8	22
83	Alemtuzumab for the treatment of relapsingâ€“remitting multiple sclerosis. <i>Immunotherapy</i> , 2014, 6, 249-259.	1.0	20
84	Effect of Ozanimod on Symbol Digit Modalities Test Performance in Relapsing MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 48, 102673.	0.9	20
85	Ozanimod in relapsing multiple sclerosis: Pooled safety results from the clinical development program. <i>Multiple Sclerosis and Related Disorders</i> , 2021, 51, 102844.	0.9	19
86	Emerging Oral Therapies in Multiple Sclerosis. <i>Current Neurology and Neuroscience Reports</i> , 2010, 10, 381-388.	2.0	18
87	Clinical features and outcomes of COVID-19 despite SARS-CoV-2 vaccination in people with multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110571.	0.5	16
88	Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Up to 5â€“years of follow-up in the DAYBREAK open-label extension trial. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1944-1962.	1.4	16
89	Multiple sclerosis, porphyria-like symptoms, and a history of iron deficiency anemia in a family of Scottish descent. , 1999, 86, 194-196.		15
90	Safety results of administering ocrelizumab per a shorter infusion protocol in patients with primary progressive and relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102454.	0.9	15

#	ARTICLE	IF	CITATIONS
91	Potential mechanisms of efficacy and adverse effects in the use of fingolimod (FTY720). Expert Review of Clinical Pharmacology, 2011, 4, 567-570.	1.3	14
92	Improvement of internuclear ophthalmoparesis in multiple sclerosis with dalfampridine. Neurology, 2014, 83, 192-194.	1.5	14
93	Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up. Journal of the Neurological Sciences, 2019, 407, 116498.	0.3	14
94	CNS disease diminishes the therapeutic functionality of bone marrow mesenchymal stem cells. Experimental Neurology, 2017, 295, 222-232.	2.0	13
95	Developing therapeutic strategies to promote myelin repair in multiple sclerosis. Expert Review of Neurotherapeutics, 2019, 19, 997-1013.	1.4	13
96	Perspectives of individuals with multiple sclerosis on discontinuation of disease-modifying therapies. Multiple Sclerosis Journal, 2020, 26, 1581-1589.	1.4	13
97	Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions. Multiple Sclerosis Journal, 2022, 28, 1131-1137.	1.4	13
98	Technology-enabled assessments to enhance multiple sclerosis clinical care and research. Neurology: Clinical Practice, 2020, 10, 222-231.	0.8	12
99	Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: Post hoc analysis of Phase 3 ozanimod trials. European Journal of Neurology, 2021, 28, 3722-3730.	1.7	12
100	Clemastine fumarate for promotion of optic nerve remyelination. Lancet, The, 2017, 390, 2421-2422.	6.3	11
101	Technology-enabled comprehensive characterization of multiple sclerosis in clinical practice. Multiple Sclerosis and Related Disorders, 2020, 38, 101525.	0.9	11
102	Multiple sclerosis: advances in understanding pathogenesis and emergence of oral treatment options. Lancet Neurology, The, 2011, 10, 4-5.	4.9	10
103	Handbook of Multiple Sclerosis. , 2012, , .		9
104	Venous angioplasty for "CCSVI" in multiple sclerosis. Neurology, 2014, 83, 388-389.	1.5	8
105	Fingolimod failure in progressive MS INFORMS future trials. Nature Reviews Neurology, 2016, 12, 253-254.	4.9	8
106	Exploratory MRI measures after intravenous autologous culture-expanded mesenchymal stem cell transplantation in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731985603.	0.5	8
107	Safety and efficacy of ADS-5102 (amantadine) extended release capsules to improve walking in multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. Multiple Sclerosis Journal, 2019, 25, 601-609.	1.4	8
108	Symptomatic and restorative therapies in neuromyelitis optica spectrum disorders. Journal of Neurology, 2022, 269, 1786-1801.	1.8	8

#	ARTICLE	IF	CITATIONS
109	Women's Health in Multiple Sclerosis: A Scoping Review. <i>Frontiers in Neurology</i> , 2021, 12, 812147.	1.1	8
110	How effective is intravenous immunoglobulin for the treatment of relapsing—remitting multiple sclerosis?. <i>Nature Clinical Practice Neurology</i> , 2008, 4, 588-589.	2.7	7
111	The future of multiple sclerosis treatment. <i>Journal of the Neurological Sciences</i> , 2009, 277, S55-S61.	0.3	7
112	Feasibility of mesenchymal stem cell culture expansion for a phase I clinical trial in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2018, 4, 205521731876528.	0.5	7
113	Lymphocyte counts and infection rates. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2019, 6, .	3.1	7
114	The emergence of follow-on disease-modifying therapies for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1560-1565.	1.4	7
115	Serum neurofilament light chain concentration in a phase 1/2 trial of autologous mesenchymal stem cell transplantation. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731988719.	0.5	7
116	Pregnancy and multiple sclerosis: Risk of unplanned pregnancy and drug exposure in utero. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2019, 5, 205521731989174.	0.5	7
117	Disability improvement as a clinically relevant outcome in clinical trials of relapsing forms of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 2219-2231.	1.4	7
118	Perspectives and experiences with COVID-19 vaccines in people with MS. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2022, 8, 205521732210852.	0.5	7
119	Fingolimod. <i>Neurology: Clinical Practice</i> , 2011, 1, 61-65.	0.8	6
120	Mesenchymal Stem Cell-derived Neural Progenitor Cells in Progressive Multiple Sclerosis: Great Expectations. <i>EBioMedicine</i> , 2018, 29, 5-6.	2.7	6
121	Early initiation of fingolimod reduces the rate of severe relapses over the long term: Post hoc analysis from the FREEDOMS, FREEDOMS II, and TRANSFORMS studies. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 36, 101335.	0.9	6
122	Palatal myoclonus, abnormal eye movements, and olivary hypertrophy in GAD65-related disorder. <i>Neurology</i> , 2020, 94, 273-275.	1.5	6
123	Newer Versus Older Treatments for Relapsing-Remitting Multiple Sclerosis. <i>Drug Safety</i> , 1996, 14, 121-130.	1.4	5
124	Integrating multiple sclerosis guidelines into practice. <i>Lancet Neurology</i> , The, 2018, 17, 658-660.	4.9	5
125	The Rise and Fall of High-Dose Biotin to Treat Progressive Multiple Sclerosis. <i>Neurotherapeutics</i> , 2020, 17, 968-970.	2.1	5
126	Response of the multiple sclerosis community to COVID-19. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1134-1136.	1.4	5

#	ARTICLE	IF	CITATIONS
127	Continuing Clinical Research During <scp>Shelterâ€™inâ€™Place</scp>. Annals of Neurology, 2020, 88, 658-660.	2.8	5
128	The benefits and risks of alemtuzumab in multiple sclerosis. Expert Review of Clinical Immunology, 2013, 9, 189-191.	1.3	4
129	Lack of magnetic resonance imaging lesion activity as a treatment target in multiple sclerosis: An evaluation using electronically collected outcomes. Multiple Sclerosis and Related Disorders, 2016, 9, 129-134.	0.9	4
130	Early age of onset predicts severity of visual impairment in patients with neuromyelitis optica spectrum disorder. Multiple Sclerosis Journal, 2021, 27, 1749-1759.	1.4	4
131	Confirming a Historical Diagnosis of Multiple Sclerosis. Neurology: Clinical Practice, 2022, 12, 263-269.	0.8	4
132	Treatment Challenges in Multiple Sclerosis â€“ A Continued Role for Glatiramer Acetate?. Frontiers in Neurology, 2022, 13, 844873.	1.1	4
133	Switching sidesâ€™fingolimod versus injectable MS therapies. Nature Reviews Neurology, 2015, 11, 316-317.	4.9	3
134	The FLUENT study design: investigating immune cell subset and neurofilament changes in patients with relapsing multiple sclerosis treated with fingolimod. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2019, 5, 205521731881924.	0.5	3
135	Keep the Worms in the Mud. JAMA Neurology, 2020, 77, 1066.	4.5	3
136	Measurement of CNS atrophy. , 0, , 128-149.		2
137	A Phase 3, double-blind, placebo-controlled efficacy and safety study of ADS-5102 (Amantadine) extended-release capsules in people with multiple sclerosis and walking impairment. Multiple Sclerosis Journal, 2022, 28, 817-830.	1.4	2
138	Appraisal of the multiple sclerosis functional composite. Expert Review of Neurotherapeutics, 2003, 3, 335-341.	1.4	1
139	Natalizumab and fingolimod: Insight into their relative efficacies in clinical practice. Multiple Sclerosis Journal, 2014, 20, 1280-1281.	1.4	1
140	Comorbidities in MS are associated with treatment intolerance and disability. Neurology, 2017, 89, 2218-2219.	1.5	1
141	Long-term ocrelizumab in progressive multiple sclerosis. Lancet Neurology, The, 2020, 19, 966-968.	4.9	1
142	Consensus Curriculum for Fellowship Training in Multiple Sclerosis and Neuroimmunology. Neurology: Clinical Practice, 2021, 11, 352-357.	0.8	1
143	MRI findings in blinded trials should be available to treating physicians â€“ No. Multiple Sclerosis Journal, 2021, 27, 814-815.	1.4	1
144	Multiple Sclerosis Wellness Shared Medical Appointment Model: A Pilot Study. International Journal of MS Care, 2021, 23, 229-233.	0.4	1

#	ARTICLE	IF	CITATIONS
145	Early versus delayed treatment with glatiramer acetate: Analysis of up to 27â€‰years of continuous follow-up in a US open-label extension study. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1729-1743.	1.4	1
146	Truncal ataxia presumably due to malignant spinal cord compression. <i>Annals of Neurology</i> , 1987, 21, 511-512.	2.8	0
147	Ligand Binding to the Cell-Surface Receptor for Reovirus Type 3 Alters Schwann Cell Growth and Function. <i>Annals of the New York Academy of Sciences</i> , 1990, 605, 412-415.	1.8	0
148	Assessment of neuropsychological function in multiple sclerosis. , 0, , 65-78.		0
149	The use of MRI in multiple sclerosis clinical trials. , 2011, , 198-212.		0
150	Treatment for patients with primary progressive multiple sclerosis. , 0, , 604-613.		0
151	Management of pediatric multiple sclerosis. , 0, , 632-644.		0
152	Management of medical comorbidities in patients with multiple sclerosis. , 0, , 714-723.		0
153	Fingolimod to treat multiple sclerosis. , 0, , 370-386.		0
154	Should MRI be the primary endpoint of phase 3 trials in multiple sclerosis?. <i>Expert Review of Clinical Immunology</i> , 2016, 12, 489-491.	1.3	0
155	Evolution of the Diagnostic Criteria in Multiple Sclerosis. , 2021, , 75-87.		0
156	Nursing, Diabetes, Hemodialysis and COVID-19. <i>Journal of Religion and Health</i> , 2022, 61, 1767-1771.	0.8	0